| Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. | Nature Medicine | 2022 | 23 |
| Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. | Lancet Oncology, The | 2022 | 11 |
| A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. | Cancer Discovery | 2022 | 7 |
| Single-cell immunology: Past, present, and future. | Immunity | 2022 | 7 |
| The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes? | Frontiers in Immunology | 2022 | 5 |
| 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? | European Thyroid Journal | 2022 | 5 |
| Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? | Journal of Hematology and Oncology | 2022 | 4 |
| Clear cell carcinoma of the endometrium. | Gynecologic Oncology | 2022 | 4 |
| What Is the Optimal Elective Colectomy for Splenic Flexure Cancer: End of the Debate? A Multicenter Study From the GRECCAR Group With a Propensity Score Analysis | Diseases of the Colon and Rectum | 2022 | 4 |
| Twin study reveals non-heritable immune perturbations in multiple sclerosis. | Nature | 2022 | 3 |
| Chk1 dynamics in G2 phase upon replication stress predict daughter cell outcome. | Developmental Cell | 2022 | 3 |
| Confocal laser endomicroscopy and confocal microscopy for head and neck cancer imaging: Recent updates and future perspectives. | Oral Oncology | 2022 | 3 |
| UBA1 gene mutation in giant cell arteritis. | Clinical Rheumatology | 2022 | 2 |
| Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease. | Journal of Thoracic Oncology | 2022 | 2 |
| Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. | Clinical and Translational Radiation Oncology | 2022 | 2 |
| Abstract GS1-10: Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST | Cancer Research | 2022 | 2 |
| The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in cancer patients and healthy individuals. | Cancer Discovery | 2022 | 2 |
| The European MAPPYACTS trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. | Cancer Discovery | 2022 | 2 |
| HSP90 mediates IFNγ-induced adaptive resistance to anti-PD-1 immunotherapy. | Cancer Research | 2022 | 2 |
| Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. | Cancer Medicine | 2022 | 1 |
| Clinical Update on Patient-Controlled Analgesia for Acute Postoperative Pain. | Pharmacy (Basel, Switzerland) | 2022 | 1 |
| Adoptive cell therapies in thoracic malignancies. | Cancer Immunology, Immunotherapy | 2022 | 1 |
| First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. | Journal of Clinical Oncology | 2022 | 1 |
| TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor. | Journal of Clinical Oncology | 2022 | 1 |
| Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. | Frontiers in Oncology | 2022 | 1 |
